Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

63
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.7K
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prematurely terminated phase 2, randomised trial to evaluate immunogenicity and reactogenicity of a single versus two-dose primary vaccination regimen of the mRNA vaccine BNT162b2 in previously SARS-CoV-2 infected children 5-11 years old (CoVacc trial).

Vaccine·2026
Same author

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same author

On the Inclusion of Non-Concurrent Controls in Platform Trials With an Interim Analysis.

Statistics in medicine·2026
Same author

A Pilot Study to Explore Length and Readability Characteristics of Subject Information Sheets/Informed Consent Forms of Clinical Trial Applications in the EU.

Clinical and translational science·2026
Same author

When randomization is not random: Allocation bias in small sample, group sequential randomized clinical trials.

Statistical methods in medical research·2026
Same author

Local Immunometabolic Intervention With Alanyl-Glutamine Resolves Peritoneal Dialysis-Induced Immune Cell Dysfunction.

Kidney international reports·2026
Same journal

Invaders taking over-Mollusc faunal change in volcanic barrier lakes of the Albertine Rift biodiversity hotspot.

PloS one·2026
Same journal

AI-driven molecular diversification and ligand-based optimization of macitentan derivatives targeting VEGFR1 and endothelin signaling pathways.

PloS one·2026
Same journal

Performance patterns and records in the world aquatics masters championships: Where do the most frequently represented nations among the top-ten masters swimmers come from?

PloS one·2026
Same journal

Modeling diurnal Temperature-Rainfall relationships under multicollinearity using PLS-SEM: A case study of Ghana.

PloS one·2026
Same journal

Organizational culture, social capital, and emergency capacity in primary healthcare institutions: A cross-sectional structural equation modeling study comparing ordinary and older communities.

PloS one·2026
Same journal

Impact of kidney function on the metabolome in the general population.

PloS one·2026
See all related articles

Related Experiment Video

Updated: Mar 14, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.2K

Optimizing Trial Designs for Targeted Therapies.

Thomas Ondra1, Sebastian Jobjörnsson2, Robert A Beckman3,4

  • 1Section for Medical Statistics, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.

Plos One
|September 30, 2016
PubMed
Summary
This summary is machine-generated.

This study optimizes clinical trial designs for targeted therapies by maximizing utility functions. It helps identify patient populations with a favorable benefit-risk balance for new treatments.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Related Experiment Videos

Last Updated: Mar 14, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.2K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Area of Science:

  • Clinical trial design
  • Decision theory
  • Biostatistics

Background:

  • Developing targeted therapies requires identifying patient populations with a positive benefit-risk balance.
  • Pivotal clinical trials assess treatment efficacy in overall or pre-specified subpopulations.
  • Optimizing trial design is crucial for efficient drug development.

Purpose of the Study:

  • To derive optimized clinical trial designs using a decision theoretic framework.
  • To maximize utility functions considering sample size, trial population, and statistical procedures.
  • To incorporate prior knowledge of drug efficacy and model diverse utility perspectives.

Main Methods:

  • Utilized a decision theoretic framework to maximize utility functions.
  • Incorporated a two-dimensional prior distribution for prior efficacy knowledge.
  • Modeled utility functions from both sponsor and public health perspectives.
  • Employed numerical optimization to determine optimal trial designs.

Main Results:

  • Developed a method for optimizing pivotal clinical trial designs.
  • Demonstrated the ability to optimize sample size, population selection, and multiple testing procedures.
  • Showcased optimized designs considering cost, expected benefit, and prior efficacy data.
  • Presented examples of optimized designs from sponsor and public health viewpoints.

Conclusions:

  • The decision theoretic framework provides an optimized approach to clinical trial design for targeted therapies.
  • This method allows for the selection of appropriate patient populations and trial parameters to ensure a positive benefit-risk balance.
  • Accounting for prior knowledge and diverse utility functions enhances the efficiency and relevance of trial designs.